About:
Carbon Biosciences is using their proprietary CBN vector library to advance gene therapy by increasing tissue specificity and allowing for larger payloads. They are developing genetic medicines utilizing next-generation viral vectors for the treatment of the most devastating and difficult-to-treat diseases. Dr. Robert Kotin, a leader in adeno-associated vector research, and John F. Engelhardt are the scientific founders of Carbon Biosciences in 2021.